TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03981211
Drug: Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
Normalized name: Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
DrugBank: Pibrentasvir (DB13878)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8 weeks of 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily or 4 weeks of 1 tablet sofosbuvir 400 mg and a three fixed-dose combination of glecaprevir/pibrentasvir 100/40 mg tablets administered once daily
Study: NCT03981211
Drug: Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 weeks of 1 x sofosbuvir (400mg) tablet and 3 x co-formulated tablets of glecaprevir (100mg) and pibrentasvir (40mg) once daily
Study: NCT04878211
Drug: Ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 3 loading doses followed by monthly administrations
Study: NCT04878211
Drug: interferon or glatiramer acetate
Normalized name: Glatiramer
DrugBank: Glatiramer (DB05259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: iDMT
Study: NCT05050760
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab 200mg IV D1，Q3W,and preoperative therapy with three cycles.
Study: NCT05050760
Drug: DCF
Normalized name: 18F DCFBC
DrugBank: DCFBC F-18 (DB14772)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCF:Oxaliplatin (85mg/ m\^2, IV D1,Q3W.Docetaxel: 60 mg/m\^2 intravenous infusion for 60 minutes, D1,Q3W.Tegafur:BSA\<1.25\^2,40 mg/time,1.25\^2\<BSA\<1.5\^2,50 mg/time,BID ,after breakfast and dinner, continuous administration for 14 days, rest for 7 days, as a treatment cycle;Repeat every 3 weeks
Study: NCT05134571
Drug: Laronidase
Normalized name: Laronidase
DrugBank: Laronidase (DB00090)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Solution for injection; Intravenous
Study: NCT04880876
Drug: 25mg Eluxadoline
Normalized name: ELUXADOLINE
DrugBank: Eluxadoline (DB09272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Tablets
Study: NCT04880876
Drug: 100mg Eluxadoline
Normalized name: eluxadoline 100 MG
DrugBank: Eluxadoline (DB09272)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral Tablets
Study: NCT05061992
Drug: Lactulose
Normalized name: Lactulose
DrugBank: Lactulose (DB00581)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will take 20 grams (dissolved in 4ounces of water/beverage) doses of lactulose twice daily (upon awakening and then 4 hours later) for 28 days.~In addition, outcome measurements will be completed at baseline and day 28.
Study: NCT05740748
Drug: Tezepelumab
Normalized name: Tezepelumab
DrugBank: Tezepelumab (DB15090)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tezepelumab 210 mg sc q4wks for 20 weeks
Study: NCT05524155
Drug: Sintilimab
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg IV d1,Q3W
Study: NCT05524155
Drug: Regorafenib
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 80mg/day,PO,QD,d1～21,Q4W
Study: NCT04756492
Drug: sandimmun
Normalized name: Sandimmune
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: follow up for treatment response
Study: NCT05743946
Drug: Trikafta
Normalized name: Trikafta
DrugBank: Ivacaftor (DB08820)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Participants will be given elexacaftor 100 mg/tezacaftor 50 mg/ivacaftor 75 mg (two pills once daily in the morning) and ivacaftor 150 mg (once daily in the evening), as the FDA-registered agent, Trikafta. Dose and schedule will be identical to what has already been FDA-approved for effective treatment of cystic fibrosis.
Study: NCT05799729
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CeK will be set at anesthesiologist's discretion. Only patients with continuous infusion of CeK 0.1, 0.2, 0.4 or 0.6 for at least 30 minutes will be considered.
Study: NCT06605586
Drug: Tasquinimod
Normalized name: Tasquinimod
DrugBank: Tasquinimod (DB05861)
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with tasquinimod capsules once daily
Study: NCT05953506
Drug: HS-10506
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10506 will be administered orally once on Day 1.
Study: NCT05015595
Drug: Memantine Oral Tablet
Normalized name: memantine Oral Tablet
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thirty-two-week double-blind up-titration treatment period (from T0 to T4): patients will be randomly assigned to one of two arms (Memantine or placebo) in a 1:1 ratio and will receive a daily administration of Memantine/placebo up to 20mg/day. Eight-week double-blind down-titration treatment period (from T4 to T5): At T4, the dose of Memantine/placebo will be reduced at 10mg/day due to safety reasons before the end of treatment (T5).
Study: NCT05891262
Drug: BMS-986196
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05891262
Drug: Loestrin
Normalized name: Lo Loestrin Fe
DrugBank: Norethisterone (DB00717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Specified dose on specified days
Study: NCT05667545
Drug: Peptide
Normalized name: Peptide
DrugBank: ACV tripeptide (DB02025)
Approvals — FDA: no, EMA: no, PMDA: no
Description: it is about synthetic protein acting on tooth structure help information apatite crystals
Study: NCT05581420
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients randomized in the oral group, will all be prescribed ferrous fumarate 200 mg d.d. for the first 4 weeks. Then, depending on their iron status, 100 mg d.d. for the following 12 weeks or 4 more weeks 200 mg d.d. followed by 4 weeks 100 mg d.d.. If iron levels are still too low after 12 weeks, the intervention has failed.
Study: NCT05581420
Drug: MonoFer
Normalized name: Monofer
DrugBank: Iron isomaltoside 1000 (DB12208)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study patients will be treated with intravenous iron. The brand name of the iv iron is dependent on the hospital policy and the doses will be according to recommended guidelines (weight of patient). Iv iron is intramural medication without add-on status and needs infusion at daycare.
Study: NCT05687448
Drug: Apixaban 5 MG Oral Tablet
Normalized name: apixaban 5 MG Oral Tablet
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients treated with apixaban 5 mg twice daily (BID)
Study: NCT05687448
Drug: warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)
DrugBank: Warfarin (DB00682)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients treated with warfarin with an objective of INR target of 2.5 (range: 2.0-3.0)
Study: NCT06608303
Drug: Topical Human Granulocyte Macrophage Stimulating Factor Gel
Normalized name: Granulocyte macrophage-colony stimulating factor
DrugBank: Molgramostim (DB12525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human granulocyte macrophage colony-stimulating factor (rhGM-CSF), as a multifunctional haematopoietic factor, stimulates the proliferation and differentiation of haematopoietic precursor cells to granulocyte macrophages and promotes their peripheral translocation, as well as enhances phagocytosis and secretion of granulocytes and macrophages \[11\]. Since macrophages are key players in regulating the inflammatory response of wounds and promoting wound repair, rhGM-CSF is thought to potentially play a positive role in the treatment of acute and chronic wounds.
Study: NCT06608303
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: placebo
Study: NCT06459869
Drug: NG-350A IV administration
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: a tumour-selective anti-CD40-expressing adenoviral vector
Study: NCT06408532
Drug: Premixed insulin
Normalized name: INSULIN
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants in this group will be have optimized premixed insulin regimen.
Study: NCT06075849
Drug: PB101
Normalized name: Phenobarbital
DrugBank: Phenobarbital (DB01174)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cohorts of 3-6 patients receive PB101 until the MTD is determined. The dose (2 mg/kg-15 mg/kg) assigned to the cohort will be administered weekly for two 28-day cycles or until progressive disease (PD), unacceptable toxicity, withdrawal of subject consent, and/or the investigator's decision to discontinue the study treatment occurs.~Administration may be continued for subjects in whom PB101 provides clinical benefits at the discretion of the investigator.
Study: NCT04478825
Drug: BBT-401-1S
Normalized name: MILNACIPRAN, (1S,2R)-
DrugBank: Levomilnacipran (DB08918)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BBT-401-1S, 8 weeks, once a day
Study: NCT05979311
Drug: Dolutegravir
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dolutegravir will be administered once daily.
Study: NCT05979311
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Lamivudine will be administered once daily.
Study: NCT05979311
Drug: Bictegravir
Normalized name: Bictegravir
DrugBank: Bictegravir (DB11799)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bictegravir will be administered once daily.
Study: NCT05979311
Drug: Emtricitabine
Normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Emtricitabine will be administered once daily.
Study: NCT05979311
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide will be administered once daily.
Study: NCT00002253
Drug: Octreotide
Normalized name: Octreotide
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05057572
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: - Arm A will receive carvedilol plus standard medical therpy,Carvedilol: will be started with initial dose of 3.125 mg BD then After 3 days, increase the dose to 6.25 mg BD, Maximum dose would be 12.5 mg BD, the same shall be switch to Maximum tollrated dose if SBP\>90, HR \>55.
Study: NCT05070754
Drug: Canthardin Collodion
Normalized name: cantharidin
DrugBank: Cantharidin (DB12328)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemical compound that acts as a vesicant to form a blister around treatment area. The blister lifts the lesion of interest away from the skin, causing it to slough off in a few days. It is used as SOC for the treatment of Molluscum Contagiosum.
Study: NCT04807751
Drug: Delgocitinib cream
Normalized name: Delgocitinib
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Cream for topical application
Study: NCT06348108
Drug: Iberdomide
Normalized name: Iberdomide
DrugBank: Iberdomide (DB12101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally (PO)
Study: NCT06348108
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT06449703
Drug: insulin degludec/liraglutide
Normalized name: INSULIN DEGLUDEC/LIRAGLUTIDE
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the abdomen.
Study: NCT05530811
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The suprazygomatic maxillary nerve block approach will be performed with a 27-gauge 38-mm needle following aseptic preparation of the skin and using the anatomical landmarks. The puncture site will be at the frontozygomatic angle formed by the zygomatic arch and posterior orbital rim. After inserting the needle perpendicular to the skin and contacting the greater wing of the sphenoid (approximately 20 mm deep), the needle will be partially withdrawn, reoriented approximately 20° anterior and 10° inferior, and advanced 35 to 38 mm to direct the needle into the pterygopalatine fossa. After negative blood aspiration, the prepared solution will be injected over 20 s on each side. Massage of injection point with pressure for 2 min will be done. No additional local anesthetic will be injected by the surgeon either peri-incisional or submucosal.
Study: NCT05530811
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% bupivacaine
Study: NCT06469060
Drug: neoadjuvant anti-PD-1 with DOC chemotherapy
Normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with one cycle of Tislelizumab 200 mg monotherapy on day~1. At 3 weeks and with intervals of 3 weeks between each cycle (weeks 3, 6, 9 and 12), patients received a total of four combination cycles consisting of Tislelizumab 200 mg, docetaxel 50 mg m-2 and oxaliplatin 100 mg m-2 intravenously at the beginning of each cycle, plus oral capecitabine 850 mg m-2 twice daily on days 1-14 of each cycle.
Study: NCT04807751
Drug: Delgocitinib cream vehicle
Normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Delgocitinib (DB16133)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.
Study: NCT06405464
Drug: VOCABRIA 30Mg Tablet
Normalized name: VOCABRIA 30mg Tablet
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAB 30 mg Film-coated tablets
Study: NCT06405464
Drug: EDURANT 25Mg Tablet
Normalized name: EDURANT 25mg Tablet
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RPV 25 mg film-coated tablets
Study: NCT06405464
Drug: Cabotegravir Injectable Suspension
Normalized name: cabotegravir Injection
DrugBank: Cabotegravir (DB11751)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CAB LA 600 mg prolonged release suspension for injection (3 mL)
Study: NCT06405464
Drug: Rilpivirine Injectable Suspension
Normalized name: rilpivirine Injection
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: RPV LA 900 mg prolonged release suspension for injection (3 mL)
Study: NCT06084130
Drug: Zolpidem
Normalized name: Zolpidem
DrugBank: Zolpidem (DB00425)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 milligrams zolpidem contained in white-color opaque medicine capsule
Study: NCT05642910
Drug: Azvudine
Normalized name: Azvudine
DrugBank: Azvudine (DB16407)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received Azvudine orally, for 7 consecutive days (7 doses in total)
Study: NCT05536323
Drug: Remimazolam bolus
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam bolus 0.14-0.33 mg/kg 0.25-0.33 mg/kg, \<40 years 0.19-0.25 mg/kg, 60-80 years 0.14-0.19 mg/kg, \>80 years
Study: NCT05536323
Drug: Remimazolam continuous
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Remimazolam 12 mg/kg/hr
Study: NCT05524545
Drug: Evorpacept
Normalized name: Evorpacept
DrugBank: Evorpacept (DB17573)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusion protein that blocks CD47-SIRPalpha pathway
Study: NCT05524545
Drug: Enfortumab Vedotin
Normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Nectin-4 directed antibody and microtubule inhibitor conjugate
Study: NCT04186286
Drug: Ivabradine 4-week course
Normalized name: milnacipran
DrugBank: Ivabradine (DB09083)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of ivabradine.
Study: NCT04186286
Drug: Propranolol 4-week course
Normalized name: milnacipran
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of propranolol.
Study: NCT04186286
Drug: Placebo 4-week course
Normalized name: milnacipran
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After a baseline screening assessment following a washout period of 7 days, participants will be randomized to start with a 4-week course of placebo
Study: NCT04842435
Drug: COVID-globulin
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a Stage 1 study, COVID globulin is administered to clinical study subjects randomized to groups 1, 2, or 3 by intravenous drip in one of three doses of 1 mL/kg, 2 mL/kg, or 4 mL/kg The initial drug administration rate is from 0.01 mL/kg to 0.02 mL/kg of body weight per minute for 30 minutes. If the drug is well tolerated, the rate of administration can be gradually increased to a maximum of 0.12 mL/kg of body weight per minute. In order to control the drug administration rate, infusion shall be performed with an infusion pump.~In a Stage 2 study, COVID globulin is administered to clinical study subjects randomized to group 1 by intravenous drip at a dose found optimal based on the results of Stage 1 study.
Study: NCT04887831
Drug: Trilaciclib
Normalized name: Trilaciclib
DrugBank: Trilaciclib (DB15442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trilaciclib administered IV prior to chemotherapy and avelumab maintenance therapy on each day chemotherapy and avelumab maintenance therapy is administered.
Study: NCT04887831
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle
Study: NCT04887831
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin administered IV on Day 1 of each 21-day cycle
Study: NCT04887831
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin administered IV on Day 1 of each 21-day cycle
Study: NCT04887831
Drug: Avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab will be dosed on Day 1 of each 14-day maintenance cycle
Study: NCT04787965
Drug: Opicapone
Normalized name: opicapone
DrugBank: Opicapone (DB11632)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Opicapone as adjunctive treatment to levodopa/carbidopa over a 6-month period
Study: NCT05432414
Drug: pomalidomide
Normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pomalidomide was administered orally at a dose of 4 mg on days 1-14 of each cycle.
Study: NCT05432414
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib was administered intravenously or subcutaneously at a dose of 1.3mg/m2 on days 1, 4, 8, 11 of each cycle.
Study: NCT05432414
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone was administered orally at a dose of 20mg on days the same and next day of bortezomib administration.
Study: NCT06597721
Drug: ADCE-T02
Normalized name: Adcetris
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered intravenously
Study: NCT05197231
Drug: IV amino acids
DrugBank: Amino acids (DB09393)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV amino acids (Glavamin, Fresenius Kabi) delivered by continuous infusion at a rate of 0.1 g/kg/h. The infusion is started immediately prior to physiotherapy and continued until all blood samples required for outcome assessment are collected during a 90-minute resting period after the exercise session.
Study: NCT01504282
Drug: mitomycin-C
Normalized name: Mitomycin-C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002418
Drug: Emivirine
Normalized name: Emivirine
DrugBank: Emivirine (DB08188)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002418
Drug: Hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002418
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002418
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002418
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05745935
Drug: Oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This study will include 100 elective cesarean section in parous women who will be randomized into two groups each of 50 patients,
Study: NCT05181995
Drug: NYX-783
Normalized name: NYX-2925
DrugBank: NYX-2925 (DB19149)
Approvals — FDA: no, EMA: no, PMDA: no
Description: NYX-783
Study: NCT05686993
Drug: Cinnarizine
Normalized name: cinnarizine
DrugBank: Cinnarizine (DB00568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cinnarizine oral 30mg TDS
Study: NCT05686993
Drug: NIFEdipine ER
Normalized name: NIFEdipine ER
DrugBank: Nifedipine (DB01115)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nifedipine oral 60mg daily extended release
Study: NCT05068661
Drug: Ropivacaine 0.1% Injectable Solution
Normalized name: ROPivacaine 0.1% injectable solution
DrugBank: Ropivacaine (DB00296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPE
Study: NCT05068661
Drug: Bupivacaine 0.25% Injectable Solution
Normalized name: BUPivacaine 0.25% injectable solution
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CSE
Study: NCT05731804
Drug: SIM0417 600 mg; Ritonavir100 mg
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: SIM0417 is single dosed, and ritonavir is administered 12 hours before SIM0417 administration (-12 hours), at the time of SIM0417 administration (0 hour), 12 hours (12 hours) after SIM0417 administration, and 24 hours (24 hours) after SIM0417 administration.